Literature DB >> 20846699

Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis.

Paola Casanova-Esteban1, Nuria Guiral, Eva Andrés, Carmen Gonzalvo, Rocio Mateo-Gallego, Pilar Giraldo, Jose A Paramo, Fernando Civeira.   

Abstract

Genetic predisposition to hereditary hemochromatosis (HH) is associated with primary hypertriglyceridemia (HTG). If iron overload influences the development of HTG, the management of these patients could be different. However, the metabolic syndrome in primary HTG is frequent; and it could partially confuse the association. The objective was to determine whether periodic bloodletting could decrease triglyceride concentrations in subjects with HH and iron overload. We retrospectively studied 155 genetically defined HH patients (C282Y homozygotes and compound heterozygotes C282Y/H63D) with iron overload and under periodic therapeutic phlebotomy. Hypertriglyceridemia (triglycerides ≥150 mg/dL) was present in 49 subjects at baseline (31.6%). Phlebotomies significantly decreased triglycerides, especially in subjects with basal HTG (from 287 mg/dL at baseline to 133 mg/dL after phlebotomies, P < .001). Blood glucose and total cholesterol did not change with phlebotomies. The triglyceride-lowering effect was obtained until ferritin concentration decreased to less than 200 μg/L and transferrin saturation to less than 40%. The triglyceride-lowering effect was obtained for glucose levels both less than and greater than 100 mg/dL. In summary, HH subjects frequently have HTG that improves after therapeutic phlebotomy, independently of basal blood glucose. Our results suggest that therapeutic phlebotomy could be a useful therapeutic approach in patients with HTG and iron overload.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20846699     DOI: 10.1016/j.metabol.2010.07.035

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

Review 1.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

2.  Iron loading impairs lipoprotein lipase activity and promotes hypertriglyceridemia.

Authors:  Jonghan Kim; Xuming Jia; Peter D Buckett; Sihao Liu; Chih-Hao Lee; Marianne Wessling-Resnick
Journal:  FASEB J       Date:  2012-12-14       Impact factor: 5.191

3.  The statin-iron nexus: anti-inflammatory intervention for arterial disease prevention.

Authors:  Leo R Zacharski; Ralph G DePalma; Galina Shamayeva; Bruce K Chow
Journal:  Am J Public Health       Date:  2013-02-14       Impact factor: 9.308

Review 4.  Pathophysiology of the Belgrade rat.

Authors:  Tania Veuthey; Marianne Wessling-Resnick
Journal:  Front Pharmacol       Date:  2014-04-22       Impact factor: 5.810

Review 5.  Atherogenesis and iron: from epidemiology to cellular level.

Authors:  Francesca Vinchi; Martina U Muckenthaler; Milene C Da Silva; György Balla; József Balla; Viktória Jeney
Journal:  Front Pharmacol       Date:  2014-05-05       Impact factor: 5.810

6.  Plasma Lipidome, PNPLA3 polymorphism and hepatic steatosis in hereditary hemochromatosis.

Authors:  Jessica Seeßle; Hongying Gan-Schreier; Marietta Kirchner; Wolfgang Stremmel; Walee Chamulitrat; Uta Merle
Journal:  BMC Gastroenterol       Date:  2020-07-17       Impact factor: 3.067

Review 7.  Non-Transferrin-Bound Iron in the Spotlight: Novel Mechanistic Insights into the Vasculotoxic and Atherosclerotic Effect of Iron.

Authors:  Francesca Vinchi
Journal:  Antioxid Redox Signal       Date:  2021-03-22       Impact factor: 8.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.